Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesPharmaco-active stents
Sang Thrombose Vaisseaux, 11/04/09
Juliard JM – The rational use of these stents requires choosing lesions at high–risk for restenosis (long lesions on small vessels, for example) in patients who can be monitored for at least one year and a dual antiplatelet therapy, which sudden discontinuation of which is a strong and independent risk factor for acute stent thrombosis with sometimes fatal consequences. These are prerequisite conditions for optimizing both the risk/benefit and cost/benefit ratios of DES. The development of full biodegradable DES stents and more effective and reproducible antiplatelet therapy is advancing to make these procedures even safer and more effective.
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Omega-3 fatty acids and heart failure
Current Atherosclerosis Reports, 11/12/09
Vitamin D and cardiovascular disease
Current Atherosclerosis Reports, 11/12/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Sponsor
Article Search
Sponsor